Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
3
Broad pipeline of novel medicines continued to progress in Q2
Approvals
| Cosentyx® US: pediatric PsO
Readouts and publications (selected)
| EntrestoⓇ
China: essential hypertension
Submissions
| LEQVIO
US: resubmission
ABL001 asciminib US, EU: chronic myeloid leukemia, 3L
US, EU: juvenile idiopathic arthritis
| Cosentyx®
Designations
AAA617
177Lu-PSMA-617
MBG453
sabatolimab
FDA Breakthrough Therapy
designation in mCRPC
FDA Fast Track designation
in myelodysplastic syndrome
See last slide for all abbreviations
9 Investor Relations | Q2 2021 Results
INNOVATION
Ph2 - PNH, IgAN, C3G (IA)
Ph2 (pivotal) r/r FL (ELARA)
Iptacopan
KymriahⓇ
ZolgensmaⓇ Ph3 - SMA (SPR1NT and STR1VE)
Ph3 - PROS (EPIK-P1)
Alpelisib
Tislelizumab Ph3 - 2L ESCC (RATIONALE 302)
BeovuⓇ
Ph3nAMD (MERLIN)
Positive
• Negative
NOVARTIS | Reimagining MedicineView entire presentation